Taiho “Primed And Ready To Go” With Colon Cancer Drug Lonsurf

After fast approval of oral chemotherapy combination Lonsurf for late-line colon cancer, U.S. oncology newcomer and Otsuka Holdings subsidiary plans to launch within two weeks at a reasonable price, says CEO Eric Benn.

Taiho Pharmaceutical Co. Ltd.’s US oncology division scored its first FDA approval Sept. 22 with early clearance of the oral fixed chemotherapy combination Lonsurf (trifluridine/tipiracil) in a very narrow indication for late-line treatment of metastatic colon cancer.

Taiho Oncology’s candidate (TAS-102) was approved for metastatic colorectal cancer (mCRC) in patients who already had fluoropyrimidine-, oxaliplatin- and irinotecan-...

More from Clinical Trials

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By 

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.

Orphan Drug Trial Sponsors ‘Playing Catch-Up’ With Regulators – But Automation Can Help

 

Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.

More from R&D